AQST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aquestive Therapeutics Inc (AQST) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company shows potential with its innovative product Anaphylm and has received positive analyst ratings, the recent FDA Complete Response Letter introduces uncertainties and delays in the approval process. Additionally, the financial performance shows declining revenue and ongoing losses, which could pose risks for a long-term investor. The technical analysis and options data do not strongly support a buy decision either.
The MACD is positive but contracting, RSI is neutral at 66.087, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 3.924, with resistance at 4.161 and support at 3.687. Overall, the technical indicators suggest a neutral trend.
Anaphylm, if approved, would be the first oral medication for severe allergic reactions, offering a unique and convenient treatment option.
Analysts view the FDA's Complete Response Letter as manageable, with no major concerns raised about the drug's efficacy or safety.
Positive sentiment from analysts with reiterated Buy ratings and price targets as high as $12.
The FDA Complete Response Letter introduces delays and uncertainties, with a resubmission planned for Q3
Financial performance shows declining revenue (-5.43% YoY) and ongoing losses, which could impact long-term growth.
No significant hedge fund or insider trading activity to indicate strong confidence in the stock.
In Q3 2025, revenue dropped by -5.43% YoY to $12.81M, while net income improved to -$15.45M, up 34.21% YoY. EPS improved slightly to -0.14, up 7.69% YoY. Gross margin declined to 64.82%, down -3.60% YoY. Overall, the company remains unprofitable with declining revenue.
Analysts are generally positive about AQST, with Buy and Outperform ratings. Price targets range from $6 to $12, reflecting optimism about the company's product pipeline despite the recent FDA setback. However, the timeline for approval and launch of Anaphylm introduces risks.
